Phaseline

Targets › MTHFR

MTHFR (Methylenetetrahydrofolate reductase): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 2 Phase 2, 2 Phase 3, 2 Phase 1, 1 Phase 4; Oncology, Psychiatry, Ophthalmology; next expected readout Dec 2026.

Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine. Represents a key regulatory connection between the folate and methionine cycles (Probable). (UniProt, P42898)

Open in Phaseline: the race on MTHFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Queen's UniversityL-methylfolate
Reduced folate cofactor; active form of folate supporting one-carbon metabolism and neurot
MTHFRPhase 4Generalized Anxiety Disorder–
Assistance Publique - Hôpitaux de ParisModified FOLFIRINOX
Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit
TOPO1, TOPO2A, MTHFR, TYMSPhase 3Rectal CancerDec 2026
Kyung Hee University Hospital at GangdongLeucovorin
Reduced folate potentiator; enhances 5-FU activity
MTHFRPhase 3Rectal Cancer–
Southwest Autism Research & Resource CenterLevoleucovorin Calcium
5-methyltetrahydrofolate (active form of folate) - cofactor for one-carbon metabolism and
MTHFRPhase 2Autism Spectrum Disorder–
National Aeronautics and Space Administration (NASA)Vitamin B-Complex Supplement
One-carbon pathway optimizer; supplies methylated B vitamins (5-methyltetrahydrofolate, ri
MTHFR, SHM1, MTHFD1, ENOSPhase 1Optic Disc EdemaJul 2027
Isofol MedicalArfolitixorin
5,10-methenyltetrahydrofolate synthetase inhibitor; active metabolite of leucovorin for 5-
MTHFRPhase 1Metastatic Colorectal Cancer (mCRC)Nov 2028

Conditions

Autism Spectrum Disorder (2) Rectal Cancer (2) Optic Disc Edema (1) Metastatic Colorectal Cancer (mCRC) (1) Generalized Anxiety Disorder (1)

Modalities

small molecule (5)

Companies

Southwest Autism Research & Resource Center (1) Kyung Hee University Hospital at Gangdong (1) Assistance Publique - Hôpitaux de Paris (1) National Aeronautics and Space Administration (NASA) (1) Isofol Medical (1) Queen's University (1)

Related targets

TOPO1 (1) TOPO2A (1) TYMS (1) SHM1 (1) MTHFD1 (1) ENOS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.